MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the year ending 2025-12-31, RLAY had -$41,052K decrease in cash & cash equivalents over the period. -$235,865K in free cash flow.

Cash Flow Overview

Change in Cash
-$41,052K
Free Cash flow
-$235,865K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
    • Proceeds from maturities and sal...
    • Depreciation expense
    • Impairment of intangible asset
    • Others
Negative Cash Flow Breakdown
    • Net loss
    • Purchases of investments
    • Accounts payable and accrued exp...
    • Others

Cash Flow
2025-12-31
Net loss
-276,479
Depreciation expense
3,557
Stock compensation expense
62,419
Impairment of intangible asset
2,300
Loss on disposal of property and equipment
-1,003
Net amortization of premiums and discounts on investments
4,949
Prepaid expenses and other current assets
-1,612
Operating lease assets and liabilities, net
4,272
Accounts payable and accrued expenses
-11,440
Deferred revenue
-7,679
Other liabilities
-1,527
Net cash used in operating activities
-235,455
Purchases of property and equipment
410
Purchases of investments
122,971
Proceeds from maturities and sales of investments
316,180
Net cash provided by (used in) investing activities
192,799
Proceeds from issuance of common stock through exercise of stock options
524
Proceeds from issuance of common stock via employee stock purchase plan
1,080
Net cash provided by financing activities
1,604
Net decrease in cash, cash equivalents, and restricted cash
-41,052
Cash, cash equivalents and restricted cash at beginning of period
126,406
Cash, cash equivalents and restricted cash at end of period
85,354
Unit: Thousand (K) dollars (except for numbers of shares and EPS).

Time Plot

Show the time plot by selecting a row from the table.

Cash Flow

Proceeds from maturitiesand sales of...$316,180K Proceeds from issuance ofcommon stock via...$1,080K Proceeds from issuance ofcommon stock through...$524K Net cash provided by(used in) investing...$192,799K Net cash provided byfinancing activities$1,604K Canceled cashflow$123,381K Net decrease incash, cash...-$41,052K Canceled cashflow$194,403K Stock compensationexpense$62,419K Depreciation expense$3,557K Impairment of intangibleasset$2,300K Prepaid expenses andother current assets-$1,612K Loss on disposal ofproperty and equipment-$1,003K Purchases of investments$122,971K Purchases of property andequipment$410K Net cash used inoperating activities-$235,455K Canceled cashflow$70,891K Net loss-$276,479K Accounts payable andaccrued expenses-$11,440K Deferred revenue-$7,679K Net amortization ofpremiums and discounts on...$4,949K Operating lease assets andliabilities, net$4,272K Other liabilities-$1,527K

Relay Therapeutics, Inc. (RLAY)

Relay Therapeutics, Inc. (RLAY)